Bangladesh

The primary regulatory authority for health products in Bangladesh is the Directorate General of Drug Administration (DGDA), operating under the Ministry of Health and Family Welfare. The principal governing legislation is the Drug (Control) Ordinance of 1982, supplemented by the Drug Policy of 1982 (revised in 2005) and subsequent amendments that have progressively expanded coverage to include medical devices, diagnostics, and digital health tools alongside pharmaceuticals. All health products intended for sale or distribution in Bangladesh must receive marketing authorization from the DGDA before they can be legally commercialized. The approval process typically involves product registration, technical dossier review, and, in some cases, laboratory testing or local clinical data requirements. Imported products face additional scrutiny compared to locally manufactured goods, reflecting the government's broader industrial policy objectives.

Applicants for product registration are generally required to appoint a local authorized agent or representative who holds legal accountability for the product within Bangladesh. Dossier submissions broadly follow the ASEAN Common Technical Dossier (ACTD) format, though the DGDA also accepts submissions aligned with the ICH Common Technical Document (CTD) structure for internationally sourced products. Key submission requirements include certificates of pharmaceutical product (CPP) from the country of origin, Good Manufacturing Practice (GMP) certification, and evidence of regulatory approval in a reference country. In recent years, the DGDA has undertaken modernization efforts including digitization of its registration portal, introduction of risk-based classification frameworks for medical devices, and steps toward harmonization with regional regulatory bodies such as those under SAARC. A dedicated Medical Device and IVD regulation framework has been under development to bring greater clarity and structure to non-pharmaceutical product categories.

Public procurement of health products in Bangladesh is coordinated primarily through the Directorate General of Health Services (DGHS) and the Directorate General of Family Planning (DGFP), both operating under the Ministry of Health and Family Welfare. Central procurement is governed by the Public Procurement Act of 2006 and the Public Procurement Rules of 2008, administered with oversight from the Central Procurement Technical Unit (CPTU) under the Ministry of Planning. Large-scale national tenders for essential medicines, vaccines, diagnostics, and medical equipment are typically managed centrally, with the Bangladesh Medical and Dental Council and relevant hospital authorities participating in facility-level procurement. The Essential Drugs Company Limited (EDCL) plays a critical role as the government's primary procurement and supply chain entity for medicines and health commodities destined for public health facilities. Procurement decisions are heavily influenced by price competitiveness, and local manufacturing preference policies provide tangible advantages to domestically produced goods, including reduced import duties and prioritization in government tender evaluations.

Bangladesh's health sector benefits from substantial donor and development partner engagement, creating parallel procurement channels alongside the public system. Major multilateral agencies including UNICEF, the World Health Organization (WHO), and the United Nations Population Fund (UNFPA) support procurement of vaccines, reproductive health commodities, and essential supplies, often through their own international competitive bidding processes. The Global Fund to Fight AIDS, Tuberculosis and Malaria finances procurement of diagnostics, therapeutics, and health system commodities for disease-specific programs, frequently channeled through principal recipients such as the Ministry of Health or designated national NGOs. USAID-funded programs, including those managed through implementing partners, support supply chain strengthening and commodity procurement in areas such as family planning and infectious disease control. Gavi, the Vaccine Alliance, is a significant partner for immunization program support, contributing to vaccine procurement at reduced prices through pooled international mechanisms. Private sector procurement occurs through a well-developed commercial pharmaceutical distribution network, with private hospitals, diagnostic centers, and retail pharmacies sourcing products from importers, local manufacturers, and authorized distributors, representing a substantial and growing share of overall health product consumption in Bangladesh.